ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor

In this work, we have analyzed the expression of different members of the ErbB family in human samples of testicular germ cell tumors (GCTs). We observed expression of ErbB1 or ErbB2 in different tumor subtypes, but we also found high expression of ErbB3 in all GCTs tested. This pattern of expressio...

ver descrição completa

Detalhes bibliográficos
Autores: Juliachs Milà, Mercè, Castillo-Ávila, Wilmar, Vidal-Bel, August, Piulats, Josep M., García del Muro Solans, Xavier, Condom i Mundó, Enric, Hernández-Losa, Javier, Teixidó, C., Pandiella, Atanasio, Graupera i Garcia-Milà, Mariona, Casanovas i Casanovas, Oriol, Germà Lluch, José Ramón, Villanueva Garatachea, Alberto, Viñals Canals, Francesc
Formato: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2013
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/120253
Acesso em linha:https://hdl.handle.net/2445/120253
Access Level:acceso abierto
Palavra-chave:Receptors cel·lulars
Medicaments antineoplàstics
Malalties del testicle
Tumors
Càncer
Cell receptors
Antineoplastic agents
Testis diseases
Cancer
id ES_09e83a3a53976db2f2f68d2202d23955
oai_identifier_str oai:recercat.cat:2445/120253
network_acronym_str ES
network_name_str España
repository_id_str
spelling ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumorJuliachs Milà, MercèCastillo-Ávila, WilmarVidal-Bel, AugustPiulats, Josep M.García del Muro Solans, XavierCondom i Mundó, EnricHernández-Losa, JavierTeixidó, C.Pandiella, AtanasioGraupera i Garcia-Milà, MarionaCasanovas i Casanovas, OriolGermà Lluch, José RamónVillanueva Garatachea, AlbertoViñals Canals, FrancescReceptors cel·lularsMedicaments antineoplàsticsMalalties del testicleTumorsCàncerCell receptorsAntineoplastic agentsTestis diseasesTumorsCancerIn this work, we have analyzed the expression of different members of the ErbB family in human samples of testicular germ cell tumors (GCTs). We observed expression of ErbB1 or ErbB2 in different tumor subtypes, but we also found high expression of ErbB3 in all GCTs tested. This pattern of expression was maintained when primary tumors were orthotopically implanted in nude mice. We have chosen a choriocarcinoma model characterized by high levels of ErbB1, but also of ErbB2 and ErbB3, to assay the in vivo effect of ErbB inhibitors on tumoral growth. Our results showed a complete lack of effect (refractoriness) to the pure ErbB1 receptor inhibitors cetuximab and gefitinib. While these inhibitors blocked ErbB1 phosphorylation, ErbB2 phosphorylation was not affected, suggesting an ErbB1-independent activation of this receptor. To confirm the importance of ErbB2 activation, animals were treated with lapatinib, a dual ErbB1 and ErbB2 inhibitor. Lapatinib treatment caused a 50% inhibition in tumor growth, an effect correlated with a blockade of both ErbB1 and ErbB2 phosphorylation levels, and of downstream signaling pathways (Akt, ERKs and Stat3). ErbB2 activation could still occur due to the formation of ErbB2/ErbB3 heterodimers, and ErbB3 activation was completely inhibited by lapatinib. Finally, combined inhibition of ErbB1 (gefitinib) and ErbB3 activities (knockdown expression by shRNA) inhibited tumoral testicular cells proliferation in a similar way to lapatinib. Our results explain why lapatinib but not anti-ErbB1 agents might be effective for treatment of testicular GCT patients.Wiley2018201820132018info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersion12 p.application/pdfhttps://hdl.handle.net/2445/120253Articles publicats en revistes (Ciències Fisiològiques)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésVersió postprint del document publicat a: https://doi.org/10.1002/ijc.28009International Journal of Cancer, 2013, vol. 133, num. 1, p. 235-246https://doi.org/10.1002/ijc.28009(c) Union for International Cancer Control (UICC), 2013info:eu-repo/semantics/openAccessoai:recercat.cat:2445/1202532026-05-29T05:05:01Z
dc.title.none.fl_str_mv ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor
title ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor
spellingShingle ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor
Juliachs Milà, Mercè
Receptors cel·lulars
Medicaments antineoplàstics
Malalties del testicle
Tumors
Càncer
Cell receptors
Antineoplastic agents
Testis diseases
Tumors
Cancer
title_short ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor
title_full ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor
title_fullStr ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor
title_full_unstemmed ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor
title_sort ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor
dc.creator.none.fl_str_mv Juliachs Milà, Mercè
Castillo-Ávila, Wilmar
Vidal-Bel, August
Piulats, Josep M.
García del Muro Solans, Xavier
Condom i Mundó, Enric
Hernández-Losa, Javier
Teixidó, C.
Pandiella, Atanasio
Graupera i Garcia-Milà, Mariona
Casanovas i Casanovas, Oriol
Germà Lluch, José Ramón
Villanueva Garatachea, Alberto
Viñals Canals, Francesc
author Juliachs Milà, Mercè
author_facet Juliachs Milà, Mercè
Castillo-Ávila, Wilmar
Vidal-Bel, August
Piulats, Josep M.
García del Muro Solans, Xavier
Condom i Mundó, Enric
Hernández-Losa, Javier
Teixidó, C.
Pandiella, Atanasio
Graupera i Garcia-Milà, Mariona
Casanovas i Casanovas, Oriol
Germà Lluch, José Ramón
Villanueva Garatachea, Alberto
Viñals Canals, Francesc
author_role author
author2 Castillo-Ávila, Wilmar
Vidal-Bel, August
Piulats, Josep M.
García del Muro Solans, Xavier
Condom i Mundó, Enric
Hernández-Losa, Javier
Teixidó, C.
Pandiella, Atanasio
Graupera i Garcia-Milà, Mariona
Casanovas i Casanovas, Oriol
Germà Lluch, José Ramón
Villanueva Garatachea, Alberto
Viñals Canals, Francesc
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Receptors cel·lulars
Medicaments antineoplàstics
Malalties del testicle
Tumors
Càncer
Cell receptors
Antineoplastic agents
Testis diseases
Tumors
Cancer
topic Receptors cel·lulars
Medicaments antineoplàstics
Malalties del testicle
Tumors
Càncer
Cell receptors
Antineoplastic agents
Testis diseases
Tumors
Cancer
description In this work, we have analyzed the expression of different members of the ErbB family in human samples of testicular germ cell tumors (GCTs). We observed expression of ErbB1 or ErbB2 in different tumor subtypes, but we also found high expression of ErbB3 in all GCTs tested. This pattern of expression was maintained when primary tumors were orthotopically implanted in nude mice. We have chosen a choriocarcinoma model characterized by high levels of ErbB1, but also of ErbB2 and ErbB3, to assay the in vivo effect of ErbB inhibitors on tumoral growth. Our results showed a complete lack of effect (refractoriness) to the pure ErbB1 receptor inhibitors cetuximab and gefitinib. While these inhibitors blocked ErbB1 phosphorylation, ErbB2 phosphorylation was not affected, suggesting an ErbB1-independent activation of this receptor. To confirm the importance of ErbB2 activation, animals were treated with lapatinib, a dual ErbB1 and ErbB2 inhibitor. Lapatinib treatment caused a 50% inhibition in tumor growth, an effect correlated with a blockade of both ErbB1 and ErbB2 phosphorylation levels, and of downstream signaling pathways (Akt, ERKs and Stat3). ErbB2 activation could still occur due to the formation of ErbB2/ErbB3 heterodimers, and ErbB3 activation was completely inhibited by lapatinib. Finally, combined inhibition of ErbB1 (gefitinib) and ErbB3 activities (knockdown expression by shRNA) inhibited tumoral testicular cells proliferation in a similar way to lapatinib. Our results explain why lapatinib but not anti-ErbB1 agents might be effective for treatment of testicular GCT patients.
publishDate 2013
dc.date.none.fl_str_mv 2013
2018
2018
2018
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/120253
url https://hdl.handle.net/2445/120253
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Versió postprint del document publicat a: https://doi.org/10.1002/ijc.28009
International Journal of Cancer, 2013, vol. 133, num. 1, p. 235-246
https://doi.org/10.1002/ijc.28009
dc.rights.none.fl_str_mv (c) Union for International Cancer Control (UICC), 2013
info:eu-repo/semantics/openAccess
rights_invalid_str_mv (c) Union for International Cancer Control (UICC), 2013
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 12 p.
application/pdf
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv Articles publicats en revistes (Ciències Fisiològiques)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403133222846464
score 15,811543